Studies in several prostate cancer mouse models have shown that RANKL inhibition with OPG-Fc or RANK-Fc can attenuate RANKL-mediated pathologic bone loss and the progression of prostate-originated tumors in bone[38], [40]. Here, TNFRSF11A is linked to prostate carcinoma.